Long-Term Safety and Tolerability of Open-Label Olanzapine Long-Acting Injection in the Treatment of Schizophrenia: 190-Week Interim Results
Open Access
- 1 January 2011
- journal article
- Published by SAGE Publications in Clinical Medicine Insights: Psychiatry
- Vol. 3 (3) , 37-47
Abstract
The primary objective of this ongoing study is to examine the long-term safety and tolerability of olanzapine long-acting injection (LAI). Current results are from a 190-week interim analysis. Patients were 18–75 years of age with schizophrenia (N = 909) or schizoaffective disorder (N = 22) previously enrolled in 1 of 3 randomized clinical trials of olanzapine LAI. In this open-label extension study, all patients received flexibly-dosed olanzapine LAI every 2–4 weeks. At time of analysis, rate of study discontinuation was 46.3%. The 18-month discontinuation rate was 34.2%. Adverse events in ≥5% of patients were increased weight, insomnia, anxiety somnolence, headache, and nasopharyngitis. There were 26 occurrences of post-injection delirium/sedation syndrome which all fully resolved within 72 hours. Mean weight change was +1.81 kg, with 32.1% of patients experiencing ≥7% weight gain. Mean Clinical Global Impressions-Severity scores remained stable throughout (2.9 at baseline to 2.8 at endpoint). Pharmacokinetic analyses indicated consistent olanzapine plasma concentrations over time, with no evidence of long-term accumulation. Safety profile was consistent with that of oral olanzapine, with the exception of findings specific to intramuscular injection. During the study period, there were 16 (1.7%) occurrences of treatment-emergent diabetes and 1 occurrence of treatment-emergent diabetic ketoacidosis. Percentages of patients with EPS scale-defined treatment-emergent akathisia, parkinsonism, and dyskinesia were 3.3%, 6.6%, and 3.0%, respectively.Keywords
This publication has 18 references indexed in Scilit:
- Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of casesBMC Psychiatry, 2010
- Olanzapine Long-Acting Injection: A 24-Week, Randomized, Double-Blind Trial of Maintenance Treatment in Patients With SchizophreniaAmerican Journal of Psychiatry, 2010
- An 8-Week, Double-Blind, Randomized, Placebo-Controlled Study of Olanzapine Long-Acting Injection in Acutely Ill Patients With SchizophreniaThe Journal of Clinical Psychiatry, 2008
- Long-term remission in schizophrenia and related psychoses with long-acting risperidone: Results obtained in an open-label study with an observation period of 18 monthsInt. Journal of Clinical Pharmacology and Therapeutics, 2008
- Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorderEuropean Neuropsychopharmacology, 2007
- Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapiesInternational Clinical Psychopharmacology, 2005
- Treatment of Schizophrenia With Long-Acting Injectable RisperidoneThe Journal of Clinical Psychiatry, 2003
- Trends in the Rate and Type of Antipsychotic Medications Prescribed to Persons With SchizophreniaSchizophrenia Bulletin, 2003
- Adherence Assessments and the Use of Depot Antipsychotics in Patients With SchizophreniaThe Journal of Clinical Psychiatry, 2001
- A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTSActa Psychiatrica Scandinavica, 1970